Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Class-I histone deacetylases (HDACs), specifically HDAC1 and HDAC2, are overexpressed in numerous cancers.
• HDAC inhibitors are currently in clinical trials, demonstrating efficacy across various cancer types.
• Understanding HDAC mechanisms is vital for developing effective cancer treatments.

Purpose of the Study:

• To review recent clinical and preclinical advancements in understanding HDAC inhibitor actions.
• To explore implications for rational drug combinations in cancer therapy.
• To elucidate the role of endogenous molecules, like S1P, in regulating HDAC activity.

Main Methods:

• Review of current clinical trial data for HDAC inhibitors.
• Analysis of preclinical research on HDAC molecular mechanisms.
• Examination of studies investigating sphingolipid mediator S1P as an HDAC regulator.

Main Results:

• HDAC1 and HDAC2 are validated targets in cancer therapy.
• HDAC inhibitors show promise when combined with conventional or targeted agents.
• Sphingolipid mediator S1P is identified as a direct intracellular target and endogenous nuclear regulator of HDACs.

Conclusions:

• New insights into HDAC molecular mechanisms inform cancer treatment strategies.
• The discovery of S1P as an HDAC regulator links nuclear sphingolipid metabolism to epigenetic control.
• Targeting endogenous HDAC regulation may lead to safer, more specific anticancer drugs.